DAVENPORT & Co LLC Has $146.64 Million Stock Position in Novo Nordisk A/S $NVO

DAVENPORT & Co LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 54.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,642,498 shares of the company’s stock after purchasing an additional 935,468 shares during the period. Novo Nordisk A/S accounts for 0.8% of DAVENPORT & Co LLC’s holdings, making the stock its 29th biggest holding. DAVENPORT & Co LLC’s holdings in Novo Nordisk A/S were worth $146,644,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of NVO. NewSquare Capital LLC raised its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $37,000. State of Wyoming acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $38,000. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $39,000. Finally, Copeland Capital Management LLC raised its position in shares of Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after acquiring an additional 186 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. The Goldman Sachs Group reduced their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, November 28th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Morgan Stanley reissued an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $53.33.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of oral Wegovy — market catalyst: The FDA cleared the first oral GLP‑1 pill for weight management, giving Novo a first‑mover commercial advantage and a path to regain share lost to Eli Lilly. Read More.
• Positive Sentiment: Launch plan and pricing expected to drive near‑term sales: Novo plans a U.S. launch in early January with an introductory cash price (~$149/month for starting dose), targeting the large self‑pay market. This gives investors a near-term revenue catalyst. Read More.
• Positive Sentiment: Unusual options activity and strong volume — investor conviction: Large call buying and much higher-than-normal trading volume indicate speculative and directional interest tied to the approval. Read More.
• Positive Sentiment: Analyst commentary supportive: Some analysts (e.g., HSBC cited in recent coverage) see Novo as having an edge over Eli Lilly after getting to market first with an oral option. Read More.
• Neutral Sentiment: ETF and sector flows may amplify moves: Approval has renewed interest in health‑care/GLP‑1 ETFs, which could lift peers and the sector irrespective of Novo’s fundamentals. Read More.
• Neutral Sentiment: Demand and reimbursement are untested for a cash‑market pill: Novo will initially push the pill into self‑pay channels, so uptake and conversion to covered prescriptions remain uncertain and could temper sales growth. Read More.
• Negative Sentiment: Competitive risk from Eli Lilly and others: Analysts warn Lilly’s oral development and its strong injectable momentum remain a material competitive threat; timing of Lilly’s response could cap upside. Read More.
• Negative Sentiment: Regulatory/generic noise in other markets: Separate regulatory delays for generics and local reimbursement issues (e.g., Canada) highlight ongoing access and pricing risks outside the U.S. Read More.

Novo Nordisk A/S Stock Up 7.4%

NVO stock opened at $51.66 on Wednesday. The stock’s 50 day simple moving average is $49.55 and its 200 day simple moving average is $57.16. The company has a market cap of $230.65 billion, a P/E ratio of 15.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.